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ALTHOUGH liver size diminishes with increasing age, neither the hepatic function nor the hepatic 
flow are significantly modified by this condition. The consideration of these facts, together with the 
aging of population and the reduced number of liver donors available, have resulted in the use of 
elder donors.1–4 Although the early function of grafts from donors above 65 years of age has been 
proven to be as good as that obtained with grafts from young donors,1,5 their late function is less 
known. 
 
MATERIALS AND METHODS 
The late hepatic function of grafts obtained from donors above 65 years old was studied. We 
reviewed two liver transplant patient groups receiving liver transplantation between January 1997 
and June 2000: (1) group A (n = 17), donors above 65 years of age; and (2) group B (n = 66), 
donors below 65 years. Donor acceptance criteria, surgical preservation and transplantation 
technique, recipient selection criteria, and postsurgery care were similar for both groups. 
The early hepatic function was studied through the following parameters: maximum AST and 
ALT values, prothrombin time activity (%) (PT), seventh-day bilirubin, length of hospital stay, 
graft primary nonfunction, and development of initial poor function (defined as elevation of ALT 
or AST above 2000 U and PT activity below 40%). The late hepatic function was characterized by 
hepatic function at 1-year post transplantation, late surgical complications, and recurrence of 
hepatic disease. Graft and patient survival curves were calculated using Kaplan–Meier estimates, 
and the different curves were compared using log-rank statistics. 
 
RESULTS 
Average donor age was 70 ± 3.8 years for group A, and 39 ± 17.2 years for group B (P < .001). 
No differences were observed between both groups regarding cause of death, length of stay in the 
intensive care unit, hypotension, and hypernatremia. Average recipient age was 61.6 ± 7.2 years 
for group A and 57.1 ± 9.1 years for group B (P = .30). No differences were observed between 
both groups regarding waiting time on the transplant list or the cause and severity of hepatic 
disease according to Child-Pugh classification. Eight recipients in group A (47%) and 24 in group 
B (36.4%) (P = .419) had hepatocarcinoma. The time of cold ischemia was 5.11 ± 1.2 hours for 
group A and 5.16 ± 1.39 hours for group B (P = .546). The times of warm ischemia were 0.65 ± 
0.17 hours and 0.62 ± 0.15 hours for groups A and B, respectively (P = .887). No differences were 
observed regarding transfusion of packed red blood cells and plasma. 
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The data of early and late post-transplant parameters are given in Table 1. There were no 
differences in maximum AST and ALT values or minimum PT and bilirubin values. No primary 
nonfunction was observed in any case; and no significant differences in the development of poor 
initial function were observed between both groups: two patients (11.7%) in group A and five 
patients (7.5%) in group B (P = .94). 
Six patients in group A (35.3%) presented late surgical complications: two with hepatic artery 
thrombosis, three with biliary fistula after removal of T tube, and one with biliary stenosis. In 
group B, a total of 17 patients (25.7%) showed late surgical complications: 11 with biliary fistules 
after removal of T tube, two with portal vein thrombosis, two with biliary stenosis, one with 
inferior vena cava stenosis, and one with arterial stenosis. 
 
After an average patient follow up of 22.9 months, the hepatic function was normal in 11 
patients (68.7%) from group A and in 44 (72.1%) from group B (P = .89). No differences were 
observed in bilirubin values at 1-year between groups A (1.08 ± 0.4 mg/dL) and B (1.42 ± 1.8 
mg/dL). Four patients in group A and 14 patients in group B show altered hepatic test results due 
to recurrent viral hepatitis in the graft. In group A, one patient died because of arterial thrombosis, 
and another patient had to undergo retransplantation for the same cause. In group B, five deaths 
occurred: two due to infections, two due to recurrent disease, and one because of a renal tumor. 
Patient survival rates at 2 years were 88.9% in group A and 93.4% in group B (P = .901). Graft 
survival rates at 2 years were 83.6% and 93.4% for groups A and B, respectively (P = .797). 
DISCUSSION 
 
Twenty percent of the liver grafts transplanted during the period of study were obtained from 
donors above 65 years of age. The consideration of these subjects as potential donors allowed for 
an expanded pool of donors with no adverse impact on short- and long-term graft function. In this 
study, the two patient groups considered were similar regarding donor, recipient, and 
transplantation characteristics affecting graft function. The excellent early function observed may 
be due to the short times of ischemia, of known significance in transplanting older livers.2,6 We 
also observed good late function with these grafts, without the appearance of the cholestatic 
pattern previously reported.2,7 Almost 60% of the patients in group A show normal function, and 
only 25% have abnormal hepatic test results due to recurrence of liver disease. These data are 
similar to what is observed with young grafts.3 Patient and graft survival rates were 88% and 83% 
respectively, also very similar to those obtained with young livers.1,2 Although the rate of surgical 
complications was similar in both groups, and none of the sepsis complications previously 
described were observed, it was noted that the arterial thrombosis only occurred with old liver 
grafts, and that was caused by technical problems and not by graft arterial damage.8
The present clinical study demonstrates good long-term results obtained with liver grafts from 
elderly donors, with times of ischemia close to 6 hours, and proves the suitability of these donors 
for any type of recipient, beyond their previous restriction to critical transplant patients. 
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Table 1. Comparision of Early and Late post-trasplant Parameters in Donors Older than 65 
Years (Group A) and Less than 65 Years (Group B) 
 
 
 
 
Group A 
(n = 17) 
Group B 
(n = 66) P 
Early    
Peak AST (IU/L) 578 663 .993 
Peak ALT (IU/L) 445 544 .996 
Minimum PT (%) 51.1 52.4 .208 
Bilirubin 7° day (mg/dL) 4.41 5.92 .208 
Poor initial function (%) 11.7 7.5 .948 
Hospital stay (days) 10.1 11.3 .677 
Late    
 
2-year patient survival (%) 88.89 93.44 .901 
2-year graft survival (%) 83.66 93.44 .797 
Surgical complications (%) 35.30 25.7 .630 
Normal liver test (%) 68.75 72.13 .890 
Bilirubin 1-year post (mg/dL) 1.08 1.42 .322 
Recurrent viral hepatitis (%) 25 22.9 .940 
 
